Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support

  • Chiara M. Grana
  • Giovanni Paganelli
Part of the Medical Radiology book series (MEDRAD)


The use of 90Y-Ibritumomab-tiuxetan as a high dose regimen should be recommended for patients with high-risk relapsed/refractory lymphoma, who can tolerate a high-dose chemotherapy treatment. Its use should be restricted to clinical trials and particular care should be given to dosimetric data; the whole therapy should be managed by a multidisciplinary team. The treatment administration can exclusively be performed in institutions which are licenced for using, labelling and administering radioactive material, as Nuclear Medicine Divisions. In several countries the licences are specific for type and amount of radionuclide: it is then requested a proper licence for the use of Yttrium-90. Labelling and administration of 90Y-Ibritumomab-tiuxetan are easy procedures. However, specific equipments have to be available, including laminar flow shielded cell, shielding protection items, radionuclide activity calibrator, quality control devices as well as devices for administration. 90Y-Ibritumomab-tiuxetan administration to the patient has to be carried out in a protected environment. Full hospitalisation with overnight stay is appropriate for clinical trials. Pre-treatment dosimetry is mandatory in research protocols, as high dose radioimmunotherapy. It is performed with imaging with 111Indium-labelled Ibritumomab-tiuxetan. Before high dose 90Y-Ibritumomab-tiuxetan administration, the patient must be informed about the therapy, the possible side effects, and sign an informed consent. After therapy on the day of discharge it is appropriate to provide the patient with written behavioural instruction, also in order to prevent anxiety related to radioactive issues.


Acute Myeloid Leukaemia Stem Cell Support Dosimetric Data Radiolabelled Antibody Peripheral Blood Stem Cell Support 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors wish to thank Mrs Deborah Console for editing the manuscript.


  1. Aricò D, Grana CM, Vanazzi A et al (2009) The role of dosimetry in the high activity 90Y-Ibritumomab-tiuxetan regimens: two cases of abnormal biodistribution. Cancer Biother Radiopharm 24(2):271–275PubMedCrossRefGoogle Scholar
  2. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRefGoogle Scholar
  3. Chinn PC, Leonard JE, Rosenberg J et al (1999) Preclinical evaluation of 90Y-labeled anti DC20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol 15:1017–1025PubMedGoogle Scholar
  4. Cremonesi M, Migliazza M, Bodei L et al (2002) Reconstruction algorithm validation for In-111-labelled radiopharmaceuticals in hybrid SPECT-CT imaging system [abstract]. Eur J Nucl Med 29(suppl):S93Google Scholar
  5. Cremonesi M, Ferrari M, Grana CM et al (2007) High-dose radioimmunotherapy with 90Y-Ibritumomab-tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med 48(11):1871–1879, Erratum in. J Nucl Med 48(12):2027Google Scholar
  6. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRefGoogle Scholar
  7. Ferrucci PF, Vanazzi A, Grana CM et al (2007) High-activity 90Y-ibritumomab-tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory = resistant B-cell non-Hodgkin’s lymphomas. Br J Haematol 139:590–599PubMedCrossRefGoogle Scholar
  8. Gopal AK, Gooley TA, Maloney DG et al (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102:2351–2357PubMedCrossRefGoogle Scholar
  9. Gopal AK, Rajendran JG, Gooley TA et al (2007) High-Dose [131I]Tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults >60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396–1402PubMedCrossRefGoogle Scholar
  10. Kaminski MS, Bennett M, Tuck M et al (2003) Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontlinetherapy with tositumomab and iodine 131 tositumomab [Abstract]. Proc Am Soc Clin Oncol 22:575Google Scholar
  11. Kantarjian HM, Keating MJ (1987) Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14:435–443PubMedGoogle Scholar
  12. Kyle RA, Greipp PR, Gertz MA et al (2000) Waldenstrom’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737–742PubMedCrossRefGoogle Scholar
  13. Liu SY, Eary JF, Petersdorf SH et al (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270–3278PubMedGoogle Scholar
  14. Morschhauser F, Illidge T, Huglo D et al (2007) Efficacy and safety of yttrium 90 Ibritumomab-tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood 110:54–58PubMedCrossRefGoogle Scholar
  15. Morschhauser F, RadfordJ, Van Hoof A, et al (2008) Phase III trial of consolidation therapy with Yttrium-90 Ibritumomab-tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164Google Scholar
  16. Nademanee A, Molina A, Dagis A et al (2000) Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin’s lymphoma. J Clin Lymph 1:46–54CrossRefGoogle Scholar
  17. Nademanee A, Forman S, Molina A et al (2005) A phase 1/2 trial of high-dose yttrium-90-Ibritumomab-tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896–2902PubMedCentralPubMedCrossRefGoogle Scholar
  18. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  19. Papi S, Martano L, Garaboldi L et al (2010) Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-Ibritumomab-tiuxetan (HD-Zevalin). Nucl Med Biol 37:85–93PubMedCrossRefGoogle Scholar
  20. Pedersen-Bjergaard J, Ersboll J, Sorensen HM et al (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas: comparison with results obtained in patients treated for Hodgkin’s disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195–200PubMedGoogle Scholar
  21. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin’s lymphoma. Engl J Med 333:1540–1545CrossRefGoogle Scholar
  22. Press OW, Eary JF, Appelbaum FR et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224PubMedCrossRefGoogle Scholar
  23. Press OW, Eary JF, Appelbaum FR et al (1995) Phase II trial of 131I–B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336–340PubMedCrossRefGoogle Scholar
  24. Savi A, Lecchi M, Albertini F et al (2004) Evaluation of attenuation correction in planar In-111 biodistribution studies [abstract]. Eur J Nucl Med Mol Imaging 31(suppl):S229Google Scholar
  25. Shen S, Forero A, LoBuglio AF et al (2005) Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46:642–651PubMedGoogle Scholar
  26. Shipp MA, Abeloff MD, Antman KH et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429PubMedGoogle Scholar
  27. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027PubMedGoogle Scholar
  28. U.S. Food and Drug Administration (2007) Web site. Review of biologics license application for IDEC pharmaceutical ZEVALIN_ kit, BLA no. 125019. Available Accessed 30 Aug 2007
  29. Vose JM, Anderson JR, Kessinger A et al (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 11:1846–1851PubMedGoogle Scholar
  30. Wiseman GA, White CA, Stabin M et al (2000) Phase I/II 90Y-Zevalin (yttrium-90 Ibritumomab-tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 27:766–777PubMedCrossRefGoogle Scholar
  31. Wiseman GA, Kornmehl E, Leigh B et al (2003a) Radiation dosimetry results and safety correlations from 90Y-Ibritumomab-tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 44:465–467PubMedGoogle Scholar
  32. Wiseman GA, Leigh BR, Dunn WL et al (2003b) Additional radiation absorbed dose estimates for ZevalinTM radioimmunotherapy. Cancer Biother Radiopharm 18:253–258PubMedCrossRefGoogle Scholar
  33. Witzig TE, Flinn IW, Gordon LI et al (2002a) Treatment with Ibritumomab-tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262–3269PubMedCrossRefGoogle Scholar
  34. Witzig TE, Gordon LI, Cabanillas F et al (2002b) Randomized controlled trial of yttrium-90-labeled Ibritumomab-tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463PubMedCrossRefGoogle Scholar
  35. Witzig TE, White CA, Gordon LI et al (2003) Safety of yttrium-90 Ibritumomab-tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 21:1263–1270PubMedCrossRefGoogle Scholar
  36. Zevalin (2007) Web site. Zevalin support services page. Available . Accessed 30 Aug 2007

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Deputy Director, Nuclear Medicine DivisionIstituto Europeo di OncologiaMilanoItaly

Personalised recommendations